<DOC>
	<DOCNO>NCT01459926</DOCNO>
	<brief_summary>A Double-Blind , Randomized , Placebo-Controlled , Parallel-Group Study Assess Safety Efficacy TD-1211 Subjects Opioid-Induced Constipation</brief_summary>
	<brief_title>A Double-Blind , Randomized , Placebo-Controlled , Parallel-Group Study Assess Safety Efficacy TD-1211 Subjects With Opioid-Induced Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>History constipation onset initiation opioid therapy Selfreported OIC approximately 3 spontaneous bowel movement ( SBMs ) per week le week least previous two week period Have use chronic opioids total daily dose â‰¥30 mg morphine equivalent unit ( MEU , Appendix 7 ) 12 week precede Screening Visit . Subjects use stable daily regimen opioids least 2 week precede Screening Visit Willing stop laxative bowel regimen exception bisacodyl/enema treatment allow per protocol throughout OIC confirmation , treatment , followup period Have participate clinical trial investigational drug medical device within 30 day prior Screening Have condition may affect drug absorption , ( e.g. , previous GI surgery ) Any condition , opinion investigator , could confound interfere evaluation safety tolerability investigational drug , prevent compliance study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Opioid induce constipation</keyword>
	<keyword>OIC</keyword>
	<keyword>Constipation</keyword>
	<keyword>Opioid side effect</keyword>
	<keyword>Morphine induce constipation</keyword>
	<keyword>Opioid therapy</keyword>
</DOC>